Canatu Oyj - Income Statement
Canatu Oyj
Helsinki First North


Revenue

Canatu's revenue has experienced a significant decline in the last quarter, with a 42.7% decrease compared to the same period in the previous year. This downturn is largely attributed to the Semiconductor business unit, which saw a substantial 92.7% drop in revenue, primarily due to the lack of new reactor orders and a major customer's inventory management strategy. Conversely, the Robotics, Mobility, and Defence business unit demonstrated a notable increase in revenue, driven by the completion of engineering projects. Canatu's revenue mix has undergone significant changes, which has impacted its gross profit as a percentage of revenue. Looking ahead, Canatu's revenue is expected to remain challenging, with the Semiconductor business unit likely to continue facing difficulties, while the Robotics, Mobility, and Defence unit may provide some growth momentum.

The realised revenue for Q2 2026 is 2.1 million Euros, and the predicted revenue for Q2 2027 (e) is also 2.1 million Euros. The revenue is expected to remain the same in one year, resulting in no change in millions, and a 0% change in percentage terms. The revenue is expected to decrease by 7.3 million Euros from 2025 to 2026, which is a 47% change. From 2026 to 2027, the revenue is expected to remain the same, resulting in no change in millions of Euros, and a 0% change in percentage terms. The annual revenue values are 15.6 million Euros in 2025, 8.3 million Euros in 2026, and 8.3 million Euros in 2027.





Ebit

Canatu's EBIT profitability has experienced a significant decline, primarily driven by increased operating expenses resulting from higher headcount, research and development activity, and expanded factory capacity. This escalation in costs has outpaced the company's ability to maintain profitability, leading to a substantial decrease in EBIT. Furthermore, the increase in depreciation and amortization expenses has also contributed to the decline in EBIT profitability. Canatu's inability to effectively manage its operating expenses and optimize its cost structure has hindered its ability to maintain profitability. The company's focus on expanding its operations and investing in research and development has created a temporary strain on its profitability, which is expected to be addressed through operational efficiencies and strategic initiatives.

The realised Ebit for Q2 2026 is -6.4 million Euros, while the predicted Ebit for Q2 2027 (e) is -4.7 million Euros. The expected change in Ebit from Q2 2026 to Q2 2027 (e) is 1.7 million Euros, which represents a 26.6% improvement. The Ebit is expected to decrease by 13.5 million Euros from 2025 to 2026, which is a 127% increase in the loss compared to the previous year. From 2026 to 2027, the Ebit is expected to decrease by 6.1 million Euros, which is a 25% decrease in the loss compared to the previous year. The annual Ebit values are -10.7 million Euros in 2025, -24.2 million Euros in 2026, and -18.1 million Euros in 2027.





Profit befor tax

The realised profit before tax in Q2 2026 is -6.1 million Euros, while the predicted profit before tax in Q2 2027 (e) is -4.7 million Euros. The expected change in profit before tax from Q2 2026 to Q2 2027 (e) is an increase of 1.4 million Euros, which represents a 22.95% improvement. The change in Profit before tax from 2025 to 2026 is a decrease of 14.1 million Euros, which is a 146.8% increase in the rate of decrease. From 2026 to 2027, the change is a decrease of 15.6 million Euros, which is a 67.1% increase in the rate of decrease. The annual values for Profit before tax are -9.6 million Euros in 2025, -23.7 million Euros in 2026, and -18.1 million Euros in 2027.



Profit

The realised profit for Q2 2026 is -6.1 million Euros, while the predicted profit for Q2 2027 (e) is -3.8 million Euros. The expected change in profit from Q2 2026 to Q2 2027 (e) is an increase of 2.3 million Euros, which represents a 37.7% improvement. The change in profit from 2025 to 2026 is a decrease of 11.6 million Euros, which is a 119% increase in the rate of decline. The change in profit from 2026 to 2027 is a decrease of 7.9 million Euros, which is a 37% decrease in the rate of decline. The annual profit values are -9.8 million Euros in 2025, -21.4 million Euros in 2026, and -14.5 million Euros in 2027.





Bioretec Oy Cityvarasto Oyj










Disclaimer

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.

Before deciding to trade in financial instrument you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.

The data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Contact: quant@quantfactory.eu

About Us